Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp. is listed today as Pasithea Therapeutics Corp.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2021 | $30 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| Jan 2021 | $1 M | No. 1 | Under $2 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Pasithea Therapeutics Corp. chose not to state its revenue in its newest notice of a funding round (Dec 2021).
SEC Form D · Dec 2021
The industry group it chose in its notices: Other Health Care.
SEC Form D · Dec 2021
That is all the official record says: Pasithea Therapeutics Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Pasithea Therapeutics Corp. are on record.
Investors#
No investor of Pasithea Therapeutics Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 30 investors.
Largest shareholders today
Institutions holding Pasithea Therapeutics Corp. shares, as of Sep 30, 2026.
- Janus Henderson Group Ltd.$2 M9.88%
- Cable Car Capital, LP$1 M8.98%
- Stonepine Capital Management, LLC$1 M8.30%
- Adage Capital Partners GP, L.L.C.$1 M6.28%
- Ameriprise Financial Inc$1 M4.13%
- AdvisorShares Investments LLC$1 M3.47%
- Vivo Capital, LLC$0 M1.12%
- Persistent Asset Partners Ltd$0 M0.87%
- Geode Capital Management, LLC$0 M0.53%
- Vanguard Fiduciary Trust Co$0 M0.52%
- Jane Street Group, LLC$0 M0.43%
- Vanguard Capital Management LLC$0 M0.38%
- XTX Topco Ltd$0 M0.37%
- HRT Financial LP$0 M0.30%
- Citadel Advisors LLC$0 M0.14%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Stanley M. Gloss | Executive officer | Dec 2021 |
| Tiago Andre Dos Reis Marques | Executive officer | Dec 2021 |
| Yassine Bendiabdallah | Executive officer | Dec 2021 |
| Craig Maxx Auringer | Executive officer | Mar 2021 |
| Israel Maxx Abramowitz | Executive officer | Mar 2021 |
| Emer Dos Reis Leahy | Director | Dec 2021 |
| Lawrence Steinman | Director | Dec 2021 |
| Simon Dumesnil | Director | Dec 2021 |
| Tiago Andre Dos Reis Marques | Director | Dec 2021 |
| Yassine Bendiabdallah | Director | Dec 2021 |
| Craig Maxx Auringer | Director | Mar 2021 |
| Israel Maxx Abramowitz | Director | Mar 2021 |
| Lawrence Reis Steinman | Director | Mar 2021 |
| Tiago Reis Marques | Director | Mar 2021 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.